Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Comment by gebremeskelon Dec 30, 2016 12:17pm
133 Views
Post# 25653913

RE:Lack of dosimetry tool linked to 4-5x over/under treatments

RE:Lack of dosimetry tool linked to 4-5x over/under treatmentsThey seem to be doing everything they can to maximize the chances of a successful human trial.

"Doing it right" is trumping "doing it soon" every time the choice comes up.

If that means delays then so be it.

bencro wrote:

Dr. Lilge was mentioning at the AGM that the lack of a reliable dosimetry tool was responsible for over or under treatments in a ratio of 4-5x.

Watch specifically @07:38-07:45 ...

Theralase AGM 2016 - Dr. Lilge on the dosimetry advantages (@05:06-09:08)

Theralase engineers have developed the TLC-3200/TLC-3400 dosimetry tool that is capable of knowing the exact number of photons per surface area delivered to the bladder wall, in order to maximize the amount of drug delivered for the treatment.

That's what we call taking control on what matters the most in order to achieve the most optimal treatment and put all the chances on our side. Brilliant.



Bullboard Posts